Akebia Therapeutics (STU:AX9) Short Ratio


STU:AX9 Akebia Therapeutics Inc STU:AX9
45 GF Score
Price €1.22
GF Value €1.10
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Akebia Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:AX9
45GF Score
Akebia Therapeutics Inc STU:AX9
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued. The current stock price of €1.22 is trading 10.5% above its estimated GF Value™ of €1.10. GuruFocus considers Akebia Therapeutics to be Fairly Valued.

Key valuation signals for STU:AX9:

  • Short Ratio:
  • GF Value™: €1.10 vs. price of €1.22 (10.5% above fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AKBA:USA
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
45GF Score

Get the complete analysis for STU:AX9

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.22
Price
€1.10
GF Value